Relief of symptoms can be achieved following surgery for growth hormone (GH)-secreting adenomas, as well as after pharmacological therapy with somatostatin analogs. Recently, long-acting somatostatin analog depot formulations, octreotide LAR and lanreotide SR have become available. Somatostatin analogs control GH/insulin-like growth factor (IGF)-1 excess, induce tumor shrinkage in a high proportion of patients, improve symptoms of acromegaly with relatively limited side effects and are successfully administered in patients not suitable for surgery. Furthermore, preoperative somatostatin analogs have been suggested to improve outcome for tumors with limited invasiveness, while surgical tumor debulking in cases that are, at least partially, somatostatin resistant, increases the achievement of normal IGF-1 levels by postoperative somatostatin analog treatment. Effective control of hypertension, as well as diabetes, is mandatory in order to reduce the increased vascular morbidity/mortality. Control of GH/IGF-1 excess generally improves glucose metabolism. Somatostatin analogs improve insulin sensitivity, exerting, however, a concomitant direct inhibitory effect on insulin secretion, with a net balance leaning towards a deterioration in glucose homeostasis. As a result, oral insulin secretagogues (and/or insulin) should probably be preferred to insulin sensitizers in acromegalic patients developing diabetes while on somatostatin analogs. Nevertheless, glucose tolerance remains normal in most of the nondiabetic acromegalic patients, while diabetic acromegalic patients on insulin are at risk for hypoglycemia during initiation of somatostatin analog therapy. Although successful management of acromegaly has been associated with improvement in morphological and functional parameters of cardiomyopathy, limited and conflicting information is available regarding the effect on blood pressure control. Contradictory results have also been reported regarding sleep hypopnea or apnea in treated acromegalic patients. As acromegalic skeletal abnormalities are rather irreversible, apneic episodes may persist after normalization of hormonal levels. Aggressive therapy, including surgery, pharmacological treatment and, in some cases, pituitary irradiation, aiming at normalization of IGF-1 levels, is required for arthropathy management. Some improvement in pain, crepitus and range of motion has been observed after treatment with somatostatin analogs. Information on the impact of disease control, either by surgery or somatostatin analog treatment, on gonadal function is limited. Finally, the link between the hormonal/biochemical and the psychiatric/psychological features of acromegaly, as well as a potential basis for positive effects of somatostatin analog therapy remain unclear.

Keywords:
Acromegaly, Somatostatin analogs, Diabetes, Hypertension, Arthropathy, Hypogonadism, Sleep apnea
1.
Culler MD: Defining the role of medical treatment as primary treatment of GH excess: pharmacology and new developments. Proc 5th Consensus Group Meet on Guidelines for treatment of GH excess and GH deficiency in the adult. February 20–22, 2006, Santa Monica.
2.
Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S: Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100:2386–2392.
3.
Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P: Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140–145.
4.
Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIH) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707–716.
5.
Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, Sheppard M: Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45:836–844.
6.
van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW: The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol 2005;63:176–184.
7.
Lamberts SW: Twenty five years of somatostatin analogs. Proc 5th Consensus Group Meet on Guidelines for treatment of GH excess and GH deficiency in the adult. February 20–22, 2006, Santa Monica.
8.
Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005;153:135–141.
9.
Wass J: Handbook of Acromegaly. Bristol, Bioscientifica, 2001.
10.
Tolis G, Yotis A, del Pozo E, Pitoulis S: Therapeutic efficacy of a somatostatin analog (SMS 201-995) in active acromegaly. J Neurosurg 1986;65:37–40.
11.
Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E: Long-term treatment of acromegaly with the somatostatin analog SMS 201-995. N Engl J Med 1985;313:1576–1580.
12.
Davies PH, Stewart SE, Lancranjan I, Sheppard MC, Stewart PM: Long-term therapy with long-acting octreotide (sandostatin LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311–316.
13.
Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G: Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J Endocrinol Invest 2005;28:978–983.
14.
Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W: Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99–104.
15.
Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM: Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 2000;53:577–586.
16.
Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM: Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090–3098.
17.
Bevan JS: Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856–1863.
18.
Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D: Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151:317–324.
19.
Freda PU: Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013–3018.
20.
Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R: Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85–92.
21.
Bevan JS: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856–1863.
22.
Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405–4410.
23.
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D: Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465–4473.
24.
Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G: Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006;91:2112–2118.
25.
Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G: Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308–3314.
26.
Ben-Shlomo A, Melmed S: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 2003;88:963–968.
27.
Petrossians P, Martins LB, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A: Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:1–7.
28.
Schmid DA, Held K, Ising M, Uhr M, Weikel JC, Steiger A: Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls. Neuropsychopharmacology 2005;30:1187–1192.
29.
Serri O, Beauregard C, Hardy J: Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89:658–661.
30.
Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N: Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549–555.
31.
Unal A, Sahin Y, Kelestimur F: Acromegaly with polycystic ovaries, hyperandrogenism, hirsutism, insulin resistance and acanthosis nigrigans: a case report. Endocr J 1993;40:207–211.
32.
Gerich J: Role of somatostatin and its analogs in the pathogenesis and treatment of diabetes mellitus. Metabolism 1990;39(suppl 2): 52S–54S.
33.
Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M: Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002;25:502–507.
34.
Lehnert H, Beyer J, Weber P, Krause U, Schrezenmeier J: Treatment of severe reactive hypoglycemia with a somatostatin analog (SMS 201-995). Arch Intern Med 1990;150:2401–2402.
35.
Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A: Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005;63:470–476.
36.
Ronconi V, Giacchetti G, Mariniello B, Camilletti A, Mantero F, Boscaro M, Vignini A, Mazzanti L: Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 2005;14:227–232.
37.
Lim MJ, Barkan AL, Buda AJ: Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992;117:719–726.
38.
Holdaway I, Rajasoorya R, Gamble G: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667–674.
39.
Lacks S, Jacobs RP: Acromegalic arthropathy: a reversible rheumatic disease. J Rheumatol 1986;13:634–636.
40.
Barcan A: Acromegalic arthropathy. Pituitary 2001;4:263–264.
41.
Barcan A: Acromegalic arthropathy and sleep apnea. J Endocrinol 1997;155(suppl 1):S41–S44.
42.
Kleinberg DL, Todd J: Evidence that human GH is a potent lactogen in primates. J Clin Endocrinol Metab 1980;51:1009–1013.
43.
Layton MW, Fudman EJ, Barca A, Braunstein EM, Fox IH: Acromegalic arthropathy: characteristics and response to therapy. Arthritis Rheum 1988;31:1022–1027.
44.
Dons RF, Rosselet P, Pastakia B, Doppman J, Gorden P: Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf) 1988;28:515–524.
45.
Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A: Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol 2001;54:183–188.
46.
Colao A, De Rosa M, Pivonello R, Balestrieri A, Cappabianca P, Di Sarno A, Rochira V, Carani C, Lombardi G: Short-term suppression of GH and IGF-1 levels improves gonadal function and sperm parameters in men with acromegaly. J Clin Endocrinol Metab 2002;87:4193–4197.
47.
Kaltsas GA, Mukherjee JJ, Jenkins PJ, Satta MA, Islam N, Monson JP, Besser GM, Grossman AB: Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999;84:2731–2735.
48.
Neal JM: Successful pregnancy in a woman with acromegaly treated with octreotide. Endocr Pract 2000;6:148–150.
49.
Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F: Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 2001;4:259–262.
50.
Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, Guillausseau PG, Warnet A, Lubetzki J: Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analog SMS 201-995. Lancet 1986;i:1270–1271.
51.
Grunstein RR, Ho KKY, Sullivan CE: Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994;121:478–483.
52.
Pelttari L, Polo O, Rauhala E, Vuoriluoto J, Aitasalo K, Hyyppa MT, Kronholm E, Irjala K, Viikari J: Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin Endocrinol (Oxf) 1995;43:175–182.
53.
Furman K, Ezzat S: Psychological features of acromegaly. Psychother Psychosom 1998;67:147–153.
54.
Kaye WH, Bailer UF, Frank GK, Wagner A, Henry SE: Brain imaging of serotonin after recovery from anorexia and bulimia nervosa. Physiol Behav 2005;86:15–17.
55.
Madsen OD, Karlsen C, Blume N, Jensen HI, Larsson LI, Holst JJ: Transplantable glucagonomas derived from pluripotent rat islet tumor tissue cause severe anorexia and adipsia. Scand J Clin Lab Invest Suppl 1995;220:27–35.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.